Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Clinical Trial

The Efficacy of Colchicine as an Adjunct Therapy in Non-hospitalized COVID-19 Patients: A Randomized Placebo-Controlled Trial

Author(s): Sepideh Hejazi, Zohreh Jahani, Sepideh Elyasi, Davoud Salarbashi and Mona Kabiri*

Volume 19, Issue 3, 2024

Published on: 06 October, 2023

Page: [254 - 263] Pages: 10

DOI: 10.2174/2772434418666230914113010

Price: $65

conference banner
Abstract

Background: The therapeutic potential of oral colchicine administration may help combat COVID-19 infection due to reduced disease severity and mortality risk.

Objective: This randomized trial aimed to assess the effect of colchicine treatment on the inflammatory and hematologic markers as well as clinical features in non-hospitalized patients with mild-to-moderate COVID-19 disease.

Methods: In the present placebo-controlled randomized trial, 80 non-hospitalized COVID-19 patients were enrolled and followed for 14 days. Subjects randomly received oral colchicine or placebo tablets once a day for two weeks. The fever and cough clinical signs, as well as Creactive protein (CRP) and lymphopenia, were evaluated through the follow-up.

Results: No significant between-group differences were observed in terms of the duration of clinical symptoms, CRP, and lymphopenia at 0, 7, and 14 days of intervention. Although the proportion of participants with fever, cough, positive CRP, and lymphopenia was higher reduced in the colchicine group than the placebo during treatment, no significant differences were found between groups. Due to no adverse effects detected in this trial, colchicine therapy was well-tolerated and safe.

Conclusion: Our findings revealed that colchicine adjuvant therapy had no beneficial effect on clinical and para-clinical parameters in non-hospitalized COVID-19 patients during 14 days of intervention. The present trial does not support colchicine as a potential treatment against COVID-19 disease.

« Previous
Graphical Abstract

[1]
Hariyanto TI, Halim DA, Jodhinata C, Yanto TA, Kurniawan A. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis. Clin Exp Pharmacol Physiol 2021; 48(6): 823-30.
[http://dx.doi.org/10.1111/1440-1681.13488] [PMID: 33719081]
[2]
Mehta KG, Patel T, Chavda PD, Patel P. Efficacy and safety of colchicine in COVID-19: A meta-analysis of randomised controlled trials. RMD Open 2021; 7(3): e001746.
[http://dx.doi.org/10.1136/rmdopen-2021-001746] [PMID: 34810227]
[3]
Pascual-Figal DA, Roura-Piloto AE, Moral-Escudero E, et al. Colchicine in recently hospitalized patients with COVID-19: A randomized controlled trial (COL-COVID). Int J Gen Med 2021; 14: 5517-26.
[http://dx.doi.org/10.2147/IJGM.S329810] [PMID: 34539185]
[4]
Pourdowlat G, Saghafi F, Mozafari A, et al. Efficacy and safety of colchicine treatment in patients with COVID ‐19: A prospective, multicenter, randomized clinical trial. Phytother Res 2022; 36(2): 891-8.
[http://dx.doi.org/10.1002/ptr.7319] [PMID: 35107188]
[5]
Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 randomized clinical trial. JAMA network open 2020; 3(6): e2013136.
[6]
Karatza E, Ismailos G, Karalis V. Colchicine for the treatment of COVID-19 patients: Efficacy, safety, and model informed dosage regimens. Xenobiotica 2021; 51(6): 643-56.
[http://dx.doi.org/10.1080/00498254.2021.1909782] [PMID: 33845715]
[7]
Absalón-Aguilar A, Rull-Gabayet M, Pérez-Fragoso A, et al. Colchicine is safe though ineffective in the treatment of severe COVID-19: A randomized clinical trial (COLCHIVID). J Gen Intern Med 2022; 37(1): 4-14.
[http://dx.doi.org/10.1007/s11606-021-07203-8] [PMID: 34755269]
[8]
Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R. Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia. Ital J Med 2020; 14(2): 88-94.
[http://dx.doi.org/10.4081/itjm.2020.1284]
[9]
Reyes AZ, Hu KA, Teperman J, et al. Anti-inflammatory therapy for COVID-19 infection: The case for colchicine. Ann Rheum Dis 2021; 80(5): 550-7.
[http://dx.doi.org/10.1136/annrheumdis-2020-219174] [PMID: 33293273]
[10]
Sarwar M, Ali Z, Fatima M, Sarfraz Z, Sarfraz A, Cherrez-Ojeda I. Colchicine, COVID‐19 and hematological parameters: A meta‐analysis. J Clin Lab Anal 2021; 35(12): e24057.
[http://dx.doi.org/10.1002/jcla.24057] [PMID: 34708886]
[11]
Schlesinger N, Firestein BL, Brunetti L. Colchicine in COVID-19: An old drug, new use. Curr Pharmacol Rep 2020; 6(4): 137-45.
[http://dx.doi.org/10.1007/s40495-020-00225-6] [PMID: 32837853]
[12]
Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial. RMD Open 2021; 7(1): e001455.
[http://dx.doi.org/10.1136/rmdopen-2020-001455] [PMID: 33542047]
[13]
Vitiello A, Ferrara F. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. Respir Med 2021; 178: 106322.
[http://dx.doi.org/10.1016/j.rmed.2021.106322] [PMID: 33550151]
[14]
Kow CS, Lee LH, Ramachandram DS, Hasan SS, Ming LC, Goh HP. The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials. Immun Inflamm Dis 2022; 10(2): 255-64.
[http://dx.doi.org/10.1002/iid3.562] [PMID: 34970856]
[15]
Salehzadeh F, Pourfarzi F, Ataei S. The impact of colchicine on COVID-19 patients: A clinical trial study. Mediterr J Rheumatol 2022; 33(2): 232-6.
[http://dx.doi.org/10.31138/mjr.33.2.232] [PMID: 36128202]
[16]
Bonaventura A, Vecchié A, Dagna L, Tangianu F, Abbate A, Dentali F. Colchicine for COVID-19: Targeting NLRP3 inflammasome to blunt hyperinflammation. Inflamm Res 2022; 71(3): 293-307.
[http://dx.doi.org/10.1007/s00011-022-01540-y] [PMID: 35113170]
[17]
Demidowich AP, Levine JA, Apps R, et al. Colchicine’s effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: Results from a pilot randomized controlled trial. Int J Obes 2020; 44(8): 1793-9.
[http://dx.doi.org/10.1038/s41366-020-0598-3] [PMID: 32461554]
[18]
Misra DP, Gasparyan AY, Zimba O. Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates. Rheumatol Int 2020; 40(11): 1741-51.
[http://dx.doi.org/10.1007/s00296-020-04694-2] [PMID: 32880032]
[19]
Sandhu T, Tieng A, Chilimuri S, Franchin G. A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection. Can J Infect Dis Med Microbiol 2020; 2020
[20]
Scarsi M, Piantoni S, Colombo E, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis 2020; 79(10): 1286-9.
[http://dx.doi.org/10.1136/annrheumdis-2020-217712] [PMID: 32732245]
[21]
Group RC. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet Respir Med 2021; 9(12): 1419-26.
[http://dx.doi.org/10.1016/S2213-2600(21)00435-5] [PMID: 34672950]
[22]
Diaz R, Orlandini A, Castellana N, Caccavo A, Corral P, Corral G. Effect of colchicine vs usual care alone on intubation and 28-day mortality in patients hospitalized with COVID-19: A randomized clinical trial. JAMA network open 2021; 4(12): e2141328.
[23]
Dorward J, Yu LM, Hayward G, et al. Colchicine for COVID-19 in the community (PRINCIPLE): A randomised, controlled, adaptive platform trial. Br J Gen Pract 2022; 72(720): e446-55.
[http://dx.doi.org/10.3399/BJGP.2022.0083] [PMID: 35440469]
[24]
Tardif JC, Bouabdallaoui N, L’Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): A phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med 2021; 9(8): 924-32.
[http://dx.doi.org/10.1016/S2213-2600(21)00222-8] [PMID: 34051877]
[25]
Golpour M, Mousavi T, Alimohammadi M, et al. The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis. Int J Immunopathol Pharmacol 2021; 35.
[http://dx.doi.org/10.1177/20587384211031763] [PMID: 34250834]
[26]
Lan SH, Hsu CK, Lai CC, et al. Effect of colchicine on the outcomes of patients with COVID-19: A systematic review and meta-analysis of randomised controlled trials. Ann Med 2022; 54(1): 1956-65.
[http://dx.doi.org/10.1080/07853890.2022.2096919] [PMID: 35833737]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy